A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma.

Trial Profile

A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Trametinib (Primary) ; Dacarbazine; Paclitaxel; Vemurafenib
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms METRIC
  • Sponsors GlaxoSmithKline; Novartis Pharma A.G.
  • Most Recent Events

    • 23 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 12 Sep 2017 5-year follow-up results (Data cutoff: Dec 16, 2016) presented at the 42nd European Society for Medical Oncology Congress
    • 11 Sep 2017 Five-year efficacy and safety results from this trial presented at the 2017 European Society for Medical Oncology Congress (ESMO) in Madrid, Spain, according to a Novartis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top